Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use

Anita Palepu1, Mark Tyndall, Benita Yip

  • 1Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Insights

Current injection drug users with HIV show poorer viral suppression on highly active antiretroviral therapy (HAART) compared to non-users. Adherence measures may be unreliable for active users, impacting treatment effectiveness.

Area of Science:

  • Virology
  • Public Health
  • Infectious Diseases

Background:

  • Highly active antiretroviral therapy (HAART) is crucial for managing HIV/AIDS.
  • Injection drug use is a significant factor influencing health outcomes in HIV-infected individuals.
  • Understanding treatment response disparities is vital for optimizing HIV care.

Purpose of the Study:

  • To compare virologic response to HAART among HIV-infected individuals based on injection drug use activity.
  • To investigate the impact of current, former, and non-injection drug use on HIV-1 RNA suppression.
  • To examine the interaction between drug use and adherence in predicting HAART efficacy.

Main Methods:

  • A population-based study of antiretroviral therapy-naive HIV-infected participants in British Columbia.
  • Classification of participants into current, former, or non-injection drug users.
  • Logistic regression analysis adjusted for baseline viral load, HAART regimen, therapy duration, adherence, and age.

Main Results:

  • Current injection drug users were significantly less likely to achieve HIV-1 RNA suppression (AOR=0.30) compared to non-drug users.
  • Former injection drug users did not show a statistically significant difference in suppression rates (AOR=0.56).
  • Adherence was positively associated with suppression in former and non-drug users, but not in current users, indicating a potential issue with adherence measurement.

Conclusions:

  • Current injection drug use is associated with reduced virologic response to HAART.
  • Pharmacy refill compliance may not be a reliable adherence measure for active injection drug users.
  • Tailored adherence support and treatment strategies are needed for HIV-infected injection drug users.

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...